v3.25.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]      
Revenue $ 185,743 $ 259,185 $ 288,945
Cost of revenue 151,753 150,876 148,743
Gross profit 33,990 108,309 140,202
Operating expenses:      
Selling, general and administrative 145,118 161,771 151,390
Research and development 17,402 19,221 17,280
Change in estimated fair value of contingent consideration 200 (2,003) (3,286)
Impairment of goodwill and long-lived assets 68,709 166,151 0
Restructuring 17,827 (1,214) 6,466
Total operating expenses 249,256 343,926 171,850
Loss from operations (215,266) (235,617) (31,648)
Other income (expense):      
Interest expense (26,992) (47,700) (45,892)
Interest income 11,436 27,403 27,727
Loss on extinguishment of debt 0 (3,187) 0
Change in payable to related parties pursuant to the Tax Receivable Agreement 0 (40) 668,886
Other expense (4,152) (2,341) (1,337)
(Loss) income before income taxes (234,974) (261,482) 617,736
Income tax (benefit) expense (4,212) (1,860) 756,111
Net loss (230,762) (259,622) (138,375)
Net loss attributable to non-controlling interests (99,989) (114,776) (19,346)
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (130,773) $ (144,846) $ (119,029)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - basic (in usd per share) $ (0.90) $ (1.05) $ (0.90)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - diluted (in usd per share) $ (0.90) $ (1.05) $ (0.90)
Weighted average Class A common shares outstanding—basic (in shares) 144,360 137,906 131,919
Weighted average Class A common shares outstanding - diluted (in shares) 144,360 137,906 131,919

Source